Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer Avelox Cardiac Safety Studies Recommended By FDA Committee

Executive Summary

Cardiac QT prolongation associated with Bayer's fluoroquinolone Avelox (moxifloxacin) should be evaluated in high risk patients, FDA's Anti-Infective Drugs Advisory Committee concluded Oct. 21.

You may also be interested in...



Bayer Avelox Skin Infection Indication "Approvable"; Needs More Safety Data

Bayer's Avelox (moxifloxacin) is "approvable" for the treatment of uncomplicated skin and skin structure infections, FDA said in a Dec. 10 letter granting the antibiotic approval for three other indications.

Bayer Avelox Skin Infection Indication "Approvable"; Needs More Safety Data

Bayer's Avelox (moxifloxacin) is "approvable" for the treatment of uncomplicated skin and skin structure infections, FDA said in a Dec. 10 letter granting the antibiotic approval for three other indications.

FDA/PhRMA Task Force To Assess QT Risk By Preclinical Markers

FDA and the Pharmaceutical Research & Manufacturers of America are forming a joint task force to define a preclinical threshold to serve as a predictor for the risk of drug-associated QT prolongation.

Related Content

UsernamePublicRestriction

Register

PS035031

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel